Kopsavilkums
Gastric cancer still represents a global health care burden, and in the absence of strategies implemented for early detection, the disease continues to have a dismal prognosis. Patients presenting with clinical manifestations of gastric cancer have limited options for cure. Thus, early detection and prevention play a key role in the fight against gastric cancer. Serologic-based test methods have the potential to detect a subset of patients at high risk of gastric cancer that require a close clinical and endoscopic follow-up. More data have been produced to support Helicobacter pylori eradication as an efficient strategy to prevent gastric cancer. Treatment options for patients with an advanced disease are still limited, but the introduction of new agents opens a more optimistic perspective for the future.
| Oriģinālvaloda | Angļu |
|---|---|
| Lapas (no-līdz) | 40-45 |
| Lapu skaits | 6 |
| Žurnāls | Helicobacter |
| Sējums | 15 |
| Izdevuma numurs | SUPPL. 1 |
| DOIs | |
| Publikācijas statuss | Publicēts - sept. 2010 |
| Ārēji publicēts | Jā |
ANO IAM
Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)
-
3. IAM — Laba Veselība un Labbūtība
Nospiedums
Uzziniet vairāk par pētniecības tēmām “Clinical Aspects of Gastric Cancer and Helicobacter pylori- Screening, Prevention, and Treatment”. Kopā tie veido unikālu nospiedumu.Citēt šo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver